TOPCAT: Aldo-Antagonist Falls Short but Impresses in HFPEFTOPCAT: Aldo-Antagonist Falls Short but Impresses in HFPEF

Spironolactone failed on the trial's primary end point, but its effect on HF hospitalizations has convinced some experts it's worth using in a disorder without other good drug options. Heartwire
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news